Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling … Read More

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

"Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically … Read More

More News

Thursday, May 18th, 2017 at 8:39am
Spark completes FDA application for gene therapy candidate to repair vision loss https://t.co/pmMHit466Z via @PHLBizJournal
Monday, May 15th, 2017 at 8:40am
Pias3 is necessary for dorso-ventral patterning and visual response of retinal cones... https://t.co/yIfnYZG21Y
Friday, May 12th, 2017 at 6:46am
A rhodopsin in the brain functions in circadian photoentrainment in Drosophila. - PubMed - NCBI https://t.co/VprhvkbYDa
Preclinical Ophthalmic Contract Research